These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30041014)

  • 41. A drug's life: the pathway to drug approval.
    Keng MK; Wenzell CM; Sekeres MA
    Clin Adv Hematol Oncol; 2013 Oct; 11(10):646-55. PubMed ID: 24518374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Product quality for nanomaterials: current U.S. experience and perspective.
    Tyner KM; Zou P; Yang X; Zhang H; Cruz CN; Lee SL
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(5):640-54. PubMed ID: 25641690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility.
    Gnanasakthy A; Norcross L; DeMuro Romano C; Carson RT
    Value Health; 2022 Apr; 25(4):647-655. PubMed ID: 35365309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
    Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlates of time to approval and other clinical development periods.
    Breder CD; VanHeusen M; Chang LC
    Drug Discov Today; 2019 Sep; 24(9):1871-1876. PubMed ID: 31170505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liposomal Drug Product Development and Quality: Current US Experience and Perspective.
    Kapoor M; Lee SL; Tyner KM
    AAPS J; 2017 May; 19(3):632-641. PubMed ID: 28160164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation.
    Kros JF; Keller CM
    Int J Electron Healthc; 2009; 5(2):164-76. PubMed ID: 19906632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Applications of In Vitro-In Vivo Correlations in Generic Drug Development: Case Studies.
    Kaur P; Jiang X; Duan J; Stier E
    AAPS J; 2015 Jul; 17(4):1035-9. PubMed ID: 25896303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The United States Food and Drugs Administration approves a generic enoxaparin.
    Ofosu FA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of Review Times for Recent 505(b)(2) Applications.
    Sakai S; DiMasi JA; Getz KA
    Ther Innov Regul Sci; 2017 Sep; 51(5):651-656. PubMed ID: 30231691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful regulatory agency interaction - A nonclinical regulatory strategist's perspective.
    Baldrick P
    Regul Toxicol Pharmacol; 2022 Apr; 130():105130. PubMed ID: 35131340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.